Daniel Adelman, MD
ADJUNCT PROFESSOR - FISCAL YR
Pulmonary, Critical Care, Allergy and Sleep Medicine
M.D., 1983 - School of Medicine, University of California Davis
- Efficacy and safety of oral immunotherapy with AR101 in European children with a peanut allergy (ARTEMIS): a multicentre, double-blind, randomised, placebo-controlled phase 3 trial.
- Latiglutenase Treatment for Celiac Disease: Symptom and Quality of Life Improvement for Seropositive Patients on a Gluten-Free Diet.
- Oral Immunotherapy for Peanut Allergy.
- AR101 Oral Immunotherapy for Peanut Allergy.
- Measuring Change In Small Intestinal Histology In Patients With Celiac Disease.
- Factors associated with villus atrophy in symptomatic coeliac disease patients on a gluten-free diet.
- A Novel Patient-Derived Conceptual Model of the Impact of Celiac Disease in Adults: Implications for Patient-Reported Outcome and Health-Related Quality-of-Life Instrument Development.
- A B-Cell Gene Signature Correlates With the Extent of Gluten-Induced Intestinal Injury in Celiac Disease.
- No Difference Between Latiglutenase and Placebo in Reducing Villous Atrophy or Improving Symptoms in Patients With Symptomatic Celiac Disease.
- Assessing Quality of Life in Patients with Common Variable Immunodeficiency: Why It Matters.
- Glutenase ALV003 attenuates gluten-induced mucosal injury in patients with celiac disease.
- Safety, tolerability, and activity of ALV003: results from two phase 1 single, escalating-dose clinical trials.
- Phase II multicenter trial of voreloxin as second-line therapy in chemotherapy-sensitive or refractory small cell lung cancer.
- Voreloxin, a first-in-class anticancer quinolone derivative, in relapsed/refractory solid tumors: a report on two dosing schedules.
- Allergen skin tests and free IgE levels during reduction and cessation of omalizumab therapy.
- A phase 1 study of SNS-032 (formerly BMS-387032), a potent inhibitor of cyclin-dependent kinases 2, 7 and 9 administered as a single oral dose and weekly infusion in patients with metastatic refractory solid tumors.
- Effects of omalizumab, a humanized monoclonal anti-IgE antibody, on nasal reactivity to allergen and local IgE synthesis.
- Phase I drug and light dose-escalation trial of motexafin lutetium and far red light activation (phototherapy) in subjects with coronary artery disease undergoing percutaneous coronary intervention and stent deployment: procedural and long-term results.
- Photodynamic therapy: applications in atherosclerotic vascular disease with motexafin lutetium.
- Pharmacological approaches.
- Photodynamic therapy with motexafin lutetium induces redox-sensitive apoptosis of vascular cells.
- Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer.
- Phase Ib trial of intravenous recombinant humanized monoclonal antibody to vascular endothelial growth factor in combination with chemotherapy in patients with advanced cancer: pharmacologic and long-term safety data.
- Photoangioplasty for human peripheral atherosclerosis: results of a phase I trial of photodynamic therapy with motexafin lutetium (Antrin).
- Letter to the editor regarding the use of intravenous immunoglobulin (IVIG) in asthma.
- Effect of aerosolized anti-IgE (E25) on airway responses to inhaled allergen in asthmatic subjects.
- A multicenter, randomized, double-blind, placebo-controlled trial of high-dose intravenous immunoglobulin for oral corticosteroid-dependent asthma.
- Down-regulation of human basophil IgE and FC epsilon RI alpha surface densities and mediator release by anti-IgE-infusions is reversible in vitro and in vivo.
- Clinical differences among women with and without self-reported perimenstrual asthma.
- Use of an anti-IgE humanized monoclonal antibody in ragweed-induced allergic rhinitis.
- Down-regulation of Fc(epsilon)RI expression on human basophils during in vivo treatment of atopic patients with anti-IgE antibody.
- CD45 isoforms on human CD4+ T-cell subsets.
- Genetic basis of the primary immunodeficiency syndromes.
- Core content outline for clinical and laboratory immunology. AAAI Training Program Directors' Committee.
- The cross-reactivity and immunology of beta-lactam antibiotics.
- Isotype-specific regulation of human lymphocyte production of immunoglobulins by sustained exposure to vasoactive intestinal peptide.
- 13-cis retinoic acid enhances in vivo B-lymphocyte differentiation in patients with common variable immunodeficiency.
- Biologic response modifiers in primary immunodeficiency disorders.
- Penicillin allergy.
- Molecular characteristics of the cellular receptor for vasoactive intestinal peptide.
- Neuropeptides, mast cells and allergy: novel mechanisms and therapeutic possibilities.
- Elevated serum interleukin-6 associated with a failure in B cell differentiation in common variable immunodeficiency.
- Acute respiratory emergencies in emergency treatment of the injured athlete.
- Abnormal T-cell subsets in normal persons.
- Fixed cutaneous eruptions to seminal-plasma challenge: a case report.
- Imipenem cross-reactivity with penicillin in humans.
- Retinoic acid induces the differentiation of B cell hybridomas from patients with common variable immunodeficiency.
- Recurrent bacterial infections and cellulitis in a 29-year-old woman with a history of hypogammaglobulinemia.
- Immediate hypersensitivity reactions to beta-lactam antibiotics.